APA (7th ed.) Citation

F, B., S, H., D, W., K, Z., G, A., E, T., . . . JC, T. (2022). Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): A multicentre, phase 3 trial. The Lancet. Oncology, 23(12), 1499. https://doi.org/10.1016/S1470-2045(22)00642-8

Chicago Style (17th ed.) Citation

F, Bénard, et al. "Intra-individual Comparison of 18F-sodium Fluoride PET-CT and 99mTc Bone Scintigraphy with SPECT in Patients with Prostate Cancer or Breast Cancer at High Risk for Skeletal Metastases (MITNEC-A1): A Multicentre, Phase 3 Trial." The Lancet. Oncology 23, no. 12 (2022): 1499. https://doi.org/10.1016/S1470-2045(22)00642-8.

MLA (9th ed.) Citation

F, Bénard, et al. "Intra-individual Comparison of 18F-sodium Fluoride PET-CT and 99mTc Bone Scintigraphy with SPECT in Patients with Prostate Cancer or Breast Cancer at High Risk for Skeletal Metastases (MITNEC-A1): A Multicentre, Phase 3 Trial." The Lancet. Oncology, vol. 23, no. 12, 2022, p. 1499, https://doi.org/10.1016/S1470-2045(22)00642-8.